AIM ImmunoTech Inc. (NYSE:AIM) CEO Buys $10,819.80 in Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels acquired 60,110 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was bought at an average cost of $0.18 per share, for a total transaction of $10,819.80. Following the completion of the transaction, the chief executive officer now directly owns 1,552,968 shares in the company, valued at $279,534.24. This represents a 4.03 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

AIM ImmunoTech Stock Performance

NYSE AIM opened at $0.21 on Friday. AIM ImmunoTech Inc. has a 12 month low of $0.16 and a 12 month high of $0.62. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a 50 day moving average of $0.26 and a 200-day moving average of $0.33.

Institutional Trading of AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC bought a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech at the end of the most recent quarter. 12.02% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Ascendiant Capital Markets dropped their price target on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Maxim Group cut their price target on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, October 22nd.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).